EPHA3 is among the most frequently mutated RTKs in human lung ADCs, and has been assigned a candidate tumor suppressor role based on its mutation spectrum and findings from in vitro and in vivo studies (Lahtela et al., 2013; Lisabeth et al., 2012; Vail et al., 2014; Zhuang et al., 2012). This evidence concerns the gene EPHA3 and neoplasm.